Site icon pharmaceutical daily

Global Biologics Contract Development and Manufacturing Organization Profiles Analysis Report 2022 –

DUBLIN–(BUSINESS WIRE)–The “Global Biologics Contract Development and Manufacturing Organization Profiles and Growth Opportunities” report has been added to’s offering.

This report provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution.

The growth of next-generation biologics and personalized therapies and the emergence of small and midsize biotechnology companies drive bio-CDMOs toward becoming end-to-end integrated service providers for better customer value creation. Next-generation biologics require outsourcing in the early stages of development.

With limited or no in-house bioprocess development capacity for new modalities, big pharmaceutical firms and small and emerging biotechnology companies seek outsourcing for these services. To support the outsourcing demand, bio-CDMOs expand to provide contract research services, leading to their adoption of the CRDMO model: contract research, development, and manufacturing.

Company profiles included in this research service offer a brief overview of the bio-CDMO’s value proposition and strategic analysis. The report also emphasizes key strategic collaborations and expansion plans across the biopharmaceutical market.

Recent expansion activities in the market reflect the increasing role of bio-CDMOs as a strategic partner in developing new modalities. Bio-CDMOs build capacity and capability to support modalities such as cell and gene therapy and mRNA.

The biopharmaceutical market is skewed toward these modalities following the success of mRNA technology in COVID-19 vaccines and therapeutics.

Research Highlights

Key Topics Covered:

1. Strategic Imperatives

2. Growth Opportunity Analysis

3. Company Profile-Lonza

3. Company Profile-Samsung Biologics

4. Company Profile-Boehringer Ingelheim BioXcellenceT

5. Company Profile-Thermo Fisher Scientific

6. Company Profile-WuXi Biologics

7. Company Profile-Catalent

8. Company Profile-AGC Biologics

9. Company Profile-WuXi AppTec

10. Growth Opportunity Universe

For more information about this report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version